Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dor BioPharma, a research and development biopharmaceutical company, has opened a new corporate office in the United Kingdom.
Subscribe to our email newsletter
The new Dor UK office gives Dor a presence in the EU to better facilitate the Named Patient Access program that will be administered by IDIS, also based in the UK. Additionally, the UK office will serve as the company’s new official interface for regulatory interactions within the EU.
The Dor UK entity will operate as Dor BioPharma UK and will be located at – BioPark, Broadwater Road, Welwyn Garden City, Hertfordshire, AL7 3AX, UK.
Christopher Schaber, president and CEO of Dor, said: “This new office will aid us in achieving our strategic vision of making orBec available to patients throughout Europe through our Named Patient Access programs while we conduct our confirmatory Phase III clinical trial.”